News Release

Durability of 2024-2025 COVID-19 vaccines against JN.1 subvariants

JAMA Internal Medicine

Peer-Reviewed Publication

JAMA Network

About The Study: The updated 2024-2025 COVID-19 vaccines provided effective protection, particularly against severe disease, although their effectiveness waned over time. Effectiveness against different subvariants was similar. 

Corresponding Author: To contact the corresponding author, Dan-Yu Lin, PhD, email lin@bios.unc.edu.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jamainternmed.2025.5465)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2025.5465?guestAccessKey=e63a57a0-14fe-4ac5-b12e-e5709dbd8d0a&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=102725

 


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.